OverviewSuggest Edit

Evoke Pharma is a pharmaceutical company, primarily focused on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
TypePublic
Founded2007
HQSolana Beach, US
Websiteevokepharma.com

Latest Updates

Employees (est.) (Feb 2019)6(-14%)
Share Price (Sept 2020)$4.4 (-6%)
Cybersecurity ratingAMore

Key People/Management at Evoke Pharma

Cam L. Garner

Cam L. Garner

Chairman

Evoke Pharma Office Locations

Evoke Pharma has an office in Solana Beach
Solana Beach, US (HQ)
420 Stevens Ave
Show all (1)

Evoke Pharma Financials and Metrics

Evoke Pharma Revenue

USD

Net income (Q2, 2020)

(7.0m)

EBIT (Q2, 2020)

(7.0m)

Market capitalization (23-Sept-2020)

115.2m

Closing stock price (23-Sept-2020)

4.4

Cash (30-Jun-2020)

8.0m

EV

109.3m
Evoke Pharma's current market capitalization is $115.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

1.6m3.2m3.7m3.6m4.1m3.9m3.7m

R&D expense

957.0k10.0m8.2m7.0m7.1m4.1m3.4m

Operating expense total

2.6m13.2m11.8m10.5m11.2m8.0m7.2m

EBIT

(2.6m)(13.2m)(11.8m)(10.5m)(11.2m)(8.0m)(7.2m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

24.2m14.2m8.7m9.0m7.7m5.3m5.7m

Accounts Receivable

Prepaid Expenses

234.3k931.5k833.3k251.0k329.2k581.7k

Inventories

Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(2.8m)(13.2m)(12.1m)(10.7m)(12.2m)(7.6m)(7.1m)

Accounts Payable

327.9k866.6k(20.5k)(276.7k)663.2k(440.4k)106.3k

Cash From Operating Activities

(3.0m)(11.5m)(10.5m)(8.7m)(8.7m)(7.0m)(5.8m)

Short-term Borrowings

(3.0m)(4.5m)
Quarterly
USDQ3, 2013

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.2 x
Show all financial metrics

Evoke Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Evoke Pharma Online and Social Media Presence

Embed Graph

Evoke Pharma News and Updates

Evoke Pharma Reports Second Quarter 2020 Financial Results

Preparing for commercial launch of GIMOTI™ in 4Q 2020 Preparing for commercial launch of GIMOTI™ in 4Q 2020

Evoke Pharma Initiates Commercial Manufacturing of Gimoti™

Preparing commercial launch of GIMOTI™ in 4Q 2020 Preparing commercial launch of GIMOTI™ in 4Q 2020

Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti™

SOLANA BEACH, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for the Gi…

Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™

EVERSANA to commercialize and distribute Gimoti in the U.S.

Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement

SOLANA BEACH, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 29, 2019, it received notification from the Listing Qualifications Department of …

Evoke Pharma Reports Third Quarter 2019 Financial Results

Gimoti NDA resubmission on track for fourth quarter 2019 Gimoti NDA resubmission on track for fourth quarter 2019
Show more

Evoke Pharma Blogs

Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price

Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price Content Import Wed, 11/13/2019 - 08:30 Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price Nov 13, 2019 This release is a backfill from a News Wire …

Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results

Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results Content Import Thu, 08/08/2019 - 05:31 Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results …

Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA

Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA Content Import Tue, 04/02/2019 - 06:05 Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA Ap…

Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA

Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA Content Import Thu, 03/14/2019 - 08:35 Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA Mar 14, 2019 This release is a backfill from a News Wire General …

Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results

Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results Content Import Wed, 02/27/2019 - 08:34 Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results Feb 27, 2019 …

Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights

Gimoti ™ NDA submitted to FDA on June 1 st ; awaiting 74-Day FDA filing communication letter Gender-specific patents granted for Gimoti in the European Union and Mexico SOLANA BEACH, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company
Show more

Evoke Pharma Frequently Asked Questions

  • When was Evoke Pharma founded?

    Evoke Pharma was founded in 2007.

  • Who are Evoke Pharma key executives?

    Evoke Pharma's key executives are Cam L. Garner.

  • How many employees does Evoke Pharma have?

    Evoke Pharma has 6 employees.

  • Who are Evoke Pharma competitors?

    Competitors of Evoke Pharma include Inovio Pharmaceuticals, Reata Pharmaceuticals and Otonomy.

  • Where is Evoke Pharma headquarters?

    Evoke Pharma headquarters is located at 420 Stevens Ave, Solana Beach.

  • Where are Evoke Pharma offices?

    Evoke Pharma has an office in Solana Beach.

  • How many offices does Evoke Pharma have?

    Evoke Pharma has 1 office.